Abstract
Anthrax is caused by infection with Bacillus anthracis, a spore forming, rod-shaped, encapsulated gram positive bacteria. The disease manifests itself in distinct ways depending on the route of entry of infective bacterial spores: cutaneous, inhalational, and gastrointestinal. Though rare in humans, inhalational anthrax has become a major concern due to the capacity for spores to be weaponized. The limited success of antibiotic therapy has motivated investigation of complementary therapeutic strategies that target the bacterias secreted toxin. The zinc-dependent metalloproteinase lethal factor (LF) is a critical component of anthrax toxin and an important potential target for small molecule drugs. In the past few years, a number of approaches have been taken to identify LF inhibitors, from generating conventional metal chelating substrate analogs to random screening of diverse compound libraries. These efforts have produced several different classes of specific nanomolar range inhibitors. Some compounds have fared well in animal models for anthrax toxemia and infection, and these inhibitors and their derivatives may form the basis for future therapies to treat the disease in humans.
Keywords: Anthrax, proteases, metalloenzymes, protease inhibitors, drug discovery, bacterial toxins
Current Pharmaceutical Biotechnology
Title: Discovery and Development of Anthrax Lethal Factor Metalloproteinase Inhibitors
Volume: 9 Issue: 1
Author(s): Benjamin E. Turk
Affiliation:
Keywords: Anthrax, proteases, metalloenzymes, protease inhibitors, drug discovery, bacterial toxins
Abstract: Anthrax is caused by infection with Bacillus anthracis, a spore forming, rod-shaped, encapsulated gram positive bacteria. The disease manifests itself in distinct ways depending on the route of entry of infective bacterial spores: cutaneous, inhalational, and gastrointestinal. Though rare in humans, inhalational anthrax has become a major concern due to the capacity for spores to be weaponized. The limited success of antibiotic therapy has motivated investigation of complementary therapeutic strategies that target the bacterias secreted toxin. The zinc-dependent metalloproteinase lethal factor (LF) is a critical component of anthrax toxin and an important potential target for small molecule drugs. In the past few years, a number of approaches have been taken to identify LF inhibitors, from generating conventional metal chelating substrate analogs to random screening of diverse compound libraries. These efforts have produced several different classes of specific nanomolar range inhibitors. Some compounds have fared well in animal models for anthrax toxemia and infection, and these inhibitors and their derivatives may form the basis for future therapies to treat the disease in humans.
Export Options
About this article
Cite this article as:
Turk E. Benjamin, Discovery and Development of Anthrax Lethal Factor Metalloproteinase Inhibitors, Current Pharmaceutical Biotechnology 2008; 9 (1) . https://dx.doi.org/10.2174/138920108783497604
DOI https://dx.doi.org/10.2174/138920108783497604 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Cyclooxygenase-2 and Prostaglandin E2 are Associated with Middle Cerebral Artery Occlusion and Hemorrhage in Patients with Moyamoya Disease
Current Neurovascular Research Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Influence of Conformationally Constrained Amino Acids Replacing Positions 2 and 3 of Arginine Vasopressin (AVP) and Its Analogues on Their Pharmacological Properties
Protein & Peptide Letters Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis
Current Medicinal Chemistry The Application of Cell-Penetrating-Peptides in Antibacterial Agents
Current Medicinal Chemistry Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Synthesis of a 2, 4, 8-Trisubstituted Pyrimidino[5, 4-d]Pyrimidine Library via Sequential SNAr Reactions on Solid-Phase
Combinatorial Chemistry & High Throughput Screening Overview: Enzyme-catalyzed Enantioselective Biotransformation of Chiral Active Compounds Used in Hypertension Treatment
Current Organic Chemistry Interaction of Carbon Monoxide with Transition Metals: Evolutionary Insights into Drug Target Discovery
Current Drug Targets Chemistry and Pharmacology of Natural Catechins from <i>Camellia sinensis</i> as Anti-MRSA Agents
Current Topics in Medicinal Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Drug-Induced Phototoxicity; An Early In Vitro Identification of Phototoxic Potential of New Drug Entities in Drug Discovery and Development
Current Drug Safety Metabolism of Rhaponticin and Activities of its Metabolite, Rhapontigenin: A Review
Current Medicinal Chemistry In Silico Studies towards Enhancing the Anticancer Activity of Phytochemical Phloretin Against Cancer Drug Targets
Current Drug Therapy Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Lipid Biomarkers in Alzheimer's Disease
Current Alzheimer Research A Medicinal Chemist’s Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents
Current Topics in Medicinal Chemistry Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology